Titre :

Th17 and cd24(hi)cd27(+) regulatory b lymphocytes are biomarkers of response to biologics in rheumatoid arthritis

Auteur(s) :

Salomon, Sarah [Auteur]
Université de Picardie Jules Verne [UPJV]
Guignant, Caroline [Auteur]
Université de Picardie Jules Verne [UPJV]
Morel, Pierre [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Flahaut, Gauthier [Auteur]
Université de Picardie Jules Verne [UPJV]
Brault, Clement [Auteur]
Université de Picardie Jules Verne [UPJV]
Gourguechon, Clement [Auteur]
Université de Picardie Jules Verne [UPJV]
Fardellone, Patrice [Auteur]
Université de Picardie Jules Verne [UPJV]
Marolleau, Jean-Pierre [Auteur]
Université de Picardie Jules Verne [UPJV]
Gubler, Brigitte [Auteur]
Université de Picardie Jules Verne [UPJV]
Goeb, Vincent [Auteur]
Université de Picardie Jules Verne [UPJV]

Titre de la revue :

Arthritis research & therapy

Nom court de la revue :

Arthritis Res. Ther.

Numéro :

19

Date de publication :

2017-02-10

ISSN :

1478-6354

Mot(s)-clé(s) en anglais :

Biomarker
Th17
Breg
Treg
Response
Anti-TNF
Abatacept
Remission
Rheumatoid arthritis
Lymphocyte
Mesh:Biomarkers/analysis
Mesh:Flow Cytometry
Mesh:Humans
Mesh:Male
Mesh:Middle Aged
Mesh:Prospective Studies
Mesh:Th17 Cells/immunology*
Mesh:Arthritis
Mesh:Rheumatoid/immunology
Mesh:Antirheumatic Agents/therapeutic use*
Mesh:Biological Products/therapeutic use
Mesh:B-Lymphocytes
Mesh:Regulatory/immunology*
Mesh:B-Lymphocyte Subsets/immunology*
Mesh:Arthritis
Mesh:Rheumatoid/drug therapy*
Mesh:Female

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

The aim was to describe the regulatory B and T cells (Breg and Treg) and T helper 17 (Th17) lymphocytes before and under treatment with biologic drugs, and to assess their potential predictive value as biomarkers of response ...
Lire la suite >The aim was to describe the regulatory B and T cells (Breg and Treg) and T helper 17 (Th17) lymphocytes before and under treatment with biologic drugs, and to assess their potential predictive value as biomarkers of response in rheumatoid arthritis (RA). This was a non-randomised, single-centre, prospective study. Patients with active RA (American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) 2010) who required the initiation or switch to any biologic drug except rituximab were included. The main judgement criterion was the frequency and absolute number of CD24hi+hihihilow-++ Thirty-one patients with RA and 17 controls were included. There was a reduction in T2/Breg frequency at M0 in patients (p < 0.001) and absolute numbers (p = 0.014) and in immunopositive vs. immunonegative RA (p = 0.016). DAS28 remission at M6 was associated with increased frequency of Treg (p = 0.01). A higher level of CD24hi+ Altogether, these data, although preliminary, suggest that phenotyping of T and B cells has potential value for the stratification of biologic drugs, notably with respect to choosing between abatacept and anti-cytokine blockade.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

CHU Lille
Université de Lille

Collections :

• METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694

Date de dépôt :

2019-12-09T18:16:05Z
2020-04-16T08:51:27Z